NCT07354191

Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia

Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia: Cross-sectional Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: New Valley University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogenic mechanisms include hyper-activation of cellular immune effectors, cytokine dysregulation, and ineffective marrow compensation.

Detailed description

AIHAs may be primary or associated with lymphoproliferative and autoimmune diseases, infections, immunodeficiencies, solid tumors, transplants, and drugs. The direct antiglobulin test is the cornerstone of diagnosis, allowing the distinction into warm forms (wAIHA), cold agglutinin disease (CAD), and other more rare forms. Multiple myeloma (MM), on the other hand, is characterized by a clonal expansion of plasma cells in bone marrow, causing bone tissue destruction, renal failure and hematopoietic suppression. Although the association of MM and anemia is common, AIHA as the anemic manifestation of MM is rare. This prospective study will be conducted to detect the presence of AIHA in MM patients and its impact on clinical presentation and outcome of the disease.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	direct antiglobulin test (DAT)	Serum sample
DIAGNOSTIC_TEST	Indirect antiglobulin test (IAT)	Serum sample

Timeline

• Start date: 2023-01-15
• Primary completion: 2025-11-05
• Completion: 2025-11-06
• First posted: 2026-01-21
• Last updated: 2026-01-21

Locations

1 site across 1 country: Egypt